On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will vote on whether seven peptides should be added to the 503A bulks list. This is the single most important regulatory event for the peptide community in years. And several of the seven peptides under review are directly relevant to women's health.
The meeting is not a formality. The outcomes are genuinely uncertain, and they will reshape access to these compounds for years to come.
What Is Happening July 23 to 24
The PCAC is an advisory body that reviews nominations for the 503A bulks list. Being on this list means a compound can be legally compounded by 503A pharmacies (traditional compounding pharmacies with individual prescriptions) using bulk active pharmaceutical ingredients. If a peptide is on the 503A list, your doctor can prescribe it and a compounding pharmacy can prepare it for you.
If a peptide is not on the list, it cannot be legally compounded by 503A pharmacies. It remains either restricted to 503B outsourcing facilities (which have stricter requirements), available only as an FDA-approved finished product (if one exists), or effectively inaccessible through legal channels.
The seven peptides being reviewed were nominated with specific clinical use cases. The PCAC will evaluate the evidence for each nomination and vote on whether the peptide meets the criteria for 503A inclusion.
The PCAC vote is advisory. The FDA makes the final decision. But the committee's recommendation carries substantial weight. A favorable vote makes 503A inclusion likely. An unfavorable vote or deferral means continued regulatory limbo.
Day One (July 23): BPC-157, KPV, TB-500, MOTS-C
BPC-157 — Nominated for Ulcerative Colitis
BPC-157 is the most widely used research peptide in the community, known for tissue repair and gut healing. Its PCAC nomination is specifically for ulcerative colitis, not the broad “healing everything” reputation it has online. The evidence base includes extensive preclinical data on gut-mucosal protection and angiogenesis, but limited human clinical trial data. Women's relevance: IBS is twice as common in women, and BPC-157 is one of the most searched gut-health peptides among female users.
KPV — Nominated for Wound Healing and Inflammatory Conditions
KPV is a tripeptide derived from alpha-MSH with potent anti-inflammatory and antimicrobial properties. It is the dark-horse candidate that industry watchers consider most likely to receive a favorable vote. The evidence for anti-inflammatory activity is robust, and wound healing applications have clear clinical utility. Women's relevance: autoimmune conditions affect women at 4 to 1 ratios, making KPV's anti-inflammatory mechanism particularly significant for the female population.
TB-500 — Nominated for Tissue Repair
TB-500 (Thymosin Beta-4) promotes tissue repair, reduces inflammation, and supports wound healing. It is commonly paired with BPC-157 in research protocols. Women's relevance: post-surgical recovery, postpartum tissue healing, and sports injury recovery are all applications where TB-500 is used.
MOTS-C — Nominated for Obesity AND Osteoporosis
MOTS-C is being evaluated for two indications simultaneously, making it unique among the seven. As a mitochondrial-derived peptide that activates AMPK, it has demonstrated effects on insulin sensitivity and bone metabolism. Women's relevance: osteoporosis is overwhelmingly a women's disease (80 percent of osteoporosis patients are female), and the obesity indication intersects directly with the metabolic features of PMOS.
Day Two (July 24): Emideltide (DSIP), Semax, Epitalon
Emideltide (DSIP) — Nominated for Sleep Disorders
Delta sleep-inducing peptide has a thin but real human evidence base. Its nomination for sleep disorders will face scrutiny over the limited clinical trial data. Women's relevance: sleep disruption is a cardinal symptom of perimenopause, and women report insomnia at roughly 1.5 times the rate of men.
Semax — Nominated for Cognitive Enhancement
Semax is a synthetic peptide based on ACTH fragments with nootropic and neuroprotective properties. It has been approved in Russia for stroke recovery and cognitive enhancement but has no FDA-approved equivalent in the US. Women's relevance: brain fog is among the most common complaints in perimenopause and PMOS, and anxiety disorders are twice as prevalent in women.
Epitalon — Nominated for Healthy Aging
Epitalon is a synthetic tetrapeptide associated with telomerase activation and pineal gland regulation. Its nomination for “healthy aging” is the broadest and most ambitious of the seven, and faces the steepest evidentiary hurdle. Women's relevance: the anti-aging peptide market skews heavily female, and estrogen's protective effects on telomere length decline after menopause.
Through a Women's Health Filter
If you had to rank the seven peptides by relevance to women's health specifically, the order would be:
1. MOTS-C — Osteoporosis indication directly addresses women's #1 long-term bone risk. Obesity indication overlaps with PMOS metabolic features.
2. KPV — Anti-inflammatory mechanism addresses autoimmune conditions that disproportionately affect women (4:1 ratio).
3. BPC-157 — Gut health indication addresses IBS (2x more common in women) and the gut-inflammation connection in PMOS.
4. Emideltide/DSIP — Sleep indication addresses perimenopausal insomnia.
5. Semax — Cognitive indication addresses brain fog in perimenopause and PMOS.
6. TB-500 — Tissue repair is gender-neutral but relevant to postpartum and post-surgical recovery.
7. Epitalon — Anti-aging market skews female, but the indication is the most thinly supported.
What Is Likely to Happen
Industry watchers and regulatory analysts generally expect a mixed result. The realistic prediction is not the blanket win that social media hype suggests.
Likely favorable: KPV has the strongest combination of evidence quality and clinical utility for its nominated indication. MOTS-C for osteoporosis has a compelling case.
Coin flip: BPC-157 has extensive preclinical data but limited human trials for its specific nominated indication (UC). MOTS-C for obesity faces more competition from existing treatments. DSIP has thin human data.
Likely deferred: Semax and Epitalon face the steepest evidentiary hurdles. Epitalon's “healthy aging” indication is extremely broad and may not meet the specificity threshold the committee typically requires.
Deferral does not mean rejection. It means the committee wants more data or a more specific nomination before voting. Deferred peptides go to a future meeting.
What the Results Mean for Access
If a peptide receives a favorable vote and the FDA follows the recommendation, it can be added to the 503A bulks list. This means your doctor can write a prescription and a compounding pharmacy can prepare it using bulk API. This dramatically improves legal access and typically reduces cost compared to research-grade sourcing.
If a peptide is not added, the status quo continues. It may still be available through 503B outsourcing facilities (which serve institutional rather than individual patients) or as research-grade material. But the legal pathway for individual prescribed use remains closed.
How to Prepare
Follow the meeting through FDA docket FDA-2025-N-6895. The proceedings will be publicly accessible. We will update this article with vote-by-vote results as they come in on July 23 and 24.
If you currently use any of these peptides and are concerned about access, this is a good time to have a conversation with your healthcare provider about your options regardless of the outcome.
PeptideOnline.co will run a live vote-by-vote tracker on July 23-24. Bookmark it now.
PCAC Live Tracker →